Skip to main content
Caplight Logo









INEYE THERAPEUTICS S.A.

INEYE THERAPEUTICS S.A.

Private
CoimbraHealthcare & Life Scienceshttps://ineyetherapeutics.com/

Last Round

VC Round

Jul 2, 2025

Total Funding Raised

$190,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

INEYE THERAPEUTICS S.A. is a biotechnology company developing a patented ocular drug delivery technology for the treatment of eye diseases such as dry eye syndrome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Revenue Share

AI Layer

Non-AI

Keywords

ocular drug deliverysustained drug releaseocular insertdrug-device combinationglaucoma treatmentdry eye treatmenteye drops replacementophthalmologypost-cataract surgerymedtechbiotechpolymeric insertclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

INEYE THERAPEUTICS S.A. Comparables

Compare INEYE THERAPEUTICS S.A. with similar companies based on industry and business-model similarity.

INEYE THERAPEUTICS S.A. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mati Therapeutics
85%
Amorphex Therapeutics
83%
PolyActiva
79%

INEYE THERAPEUTICS S.A. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 2, 2025
GrantMar 20, 2025
SeedSep 18, 2023

INEYE THERAPEUTICS S.A. Investors

Notable investors and investment history

INEYE THERAPEUTICS S.A. investors
InvestorRounds
Insight Venture – Sociedade de Capital de Risco, S.A.VC Round
Women TechEUGrant
Portugal VenturesVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 62% MoM.

  • Mar 5, 2026

    Monthly visitors grew 7117% MoM, from 6 to 433.

INEYE THERAPEUTICS S.A. Filings

Explore SEC and related filing metadata, where available.

INEYE THERAPEUTICS S.A. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about INEYE THERAPEUTICS S.A.'s valuation, stock price, and market status.

Is INEYE THERAPEUTICS S.A. a public or private company?

INEYE THERAPEUTICS S.A. is a private company.

What is the current stock price of INEYE THERAPEUTICS S.A.?

INEYE THERAPEUTICS S.A. is a private company with no public stock price. No recent secondary market data is available.

How much is INEYE THERAPEUTICS S.A. worth (valuation)?

Valuation information for INEYE THERAPEUTICS S.A. is not publicly available.

Can I buy INEYE THERAPEUTICS S.A. stock?

INEYE THERAPEUTICS S.A. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was INEYE THERAPEUTICS S.A.'s last funding round?

INEYE THERAPEUTICS S.A.'s most recent funding round was VC Round on July 2, 2025.

Who are the main investors in INEYE THERAPEUTICS S.A.?

Key investors in INEYE THERAPEUTICS S.A. include Portugal Ventures.

Will INEYE THERAPEUTICS S.A. IPO soon?

No public IPO plans have been announced for INEYE THERAPEUTICS S.A..

How can I track INEYE THERAPEUTICS S.A. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor INEYE THERAPEUTICS S.A.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCoimbra
Employee Range6
Year Founded2017
Last FundingJul 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?